A generic alternative indicated for Bone Health. Supports bone density preservation and assists in minimizing fracture risks in postmenopausal individuals.
Designed to alleviate bone density loss in postmenopausal women to address fracture risk and support long-term skeletal health and cancer prevention.
Mechanism of Action
Raloxifene acts like estrogen in some parts of the body, like the bones, to help prevent thinning. However, it blocks estrogen's effects in the breast and uterus, which helps reduce the risk of certain cancers.
Route of Administration
Oral
Onset Time
Steady state in 8 weeks
Duration
24 hours
Contraindications
History of blood clots, Active liver disease, Pregnancy, Hypersensitivity to raloxifene
Severe Adverse Events
Venous thromboembolism, Stroke, Fatal blood clots, Severe allergic reactions
Common Side Effects
Hot flashes, Leg cramps
Uncommon Side Effects
Joint pain, Flu-like symptoms, Sweating, Swelling
Drug Interactions
Warfarin, Cholestyramine, Levothyroxine, Diazepam
Pregnancy Safety Warnings
Contraindicated; can cause fetal harm.
Age Restrictions
For postmenopausal women only.
Storage Guidelines
Store at room temperature protected from moisture.
Information for Raloxifene is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
